• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novaliq touts topline data for dry eye disease drug

October 18, 2018 By Sarah Faulkner

Novaliq logo updatedNovaliq today touted topline data from the first pivotal trial of its CyclASol 0.1% drug designed to treat dry eye disease.

The company is hoping to position its 0.1% cyclosporine A product as advantageous compared to other ophthalmic treatments, noting that its EyeSol technology helps boost the drug’s efficacy and provide an earlier onset of effect.

Novaliq’s Essence Phase IIb/III trial enrolled 328 patients at sites across the U.S. and was designed to assess the safety, efficacy and tolerability of topical CyclASol 0.1% in people with aqueous-deficient dry eye disease. The study’s primary efficacy endpoint, improvement of total corneal fluorescein staining, was measured at four weeks and participants continued receiving doses for efficacy and safety considerations over the course of the three months.

The trial met its primary efficacy endpoint with high statistical significant, according to Novaliq. The company reported that, consistent with previously-held studies, the central area of the cornea benefited most from treatment with CyclASol. Novaliq also noted that participants saw the effects of CyclASol as early as two weeks into treatment and that those benefits were maintained throughout the remainder of the trial.

The study also confirmed a strong safety and tolerability profile for the drug, Novaliq said. Detailed results from the company’s Essence trial are slated to be presented by CEO Christian Roesky during the Ophthalmology Innovation Summit in Chicago later this month.

“We are very pleased with the outcomes from Essence. CyclASol 0.1% unfolds the full potential of cyclosporine for the first time in the treatment of DED and demonstrates the superior benefits of our non-aqueous, preservative-free formulation, allowing clinicians to treat more of their patients suffering from DED,” Dr. Gabriela Burian, consulting CMO for Novaliq GmbH, said in prepared remarks. “These results provide pivotal evidence and a clear direction for Novaliq to pursue a timely completion of the clinical development of CyclASol.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Research & Development Tagged With: Novaliq GmbH

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS